Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
As the first quarter comes to a close, three Bay Area life sciences companies have already gone public in 2018.
Google parent company Alphabet has had a stake in two of them.
The company's venture arm, GV (formerly known as Google Ventures), has backed nearly 60 healthcare-related companies since it raised its first fund in 2009, making it one of the most active Silicon Valley players in the space.
Those bets are starting to pay off: Five of GV's healthcare bets have gone public in the last year.
GV owned a large enough stake in four of them — 10 percent or more — to be required to report as an insider with the SEC.
The market value for the firm's combined ownership of those four companies is roughly $153 million, according to data from FactSet:
Here are the five companies, what they do, and when GV invested:
Spero Therapeutics, a biopharmaceutical company creating treatments for bacterial infections, started trading on the Nasdaq last fall and has a current market cap of $204.8 million.
GV led its Series C in March 2017 and its stake is now worth $15.79 million, according to FactSet.
Arsanis, which is working on antibody immunotherapies for infectious diseases, went public in November of last year and has a market cap of $327.2 million. GV invested in its Series D in April 2017 and its stake is worth $10.62 million, according to FactSet.
Arcus Bioscience, which develops cancer immunotherapies, went public in March and has a market cap of $657 million.
GV first invested in Arcus' Series B in 2016 and again in its Series C in 2017, and its stake is worth $80.9 million, according to FactSet.
ARMO Biosciences fights cancer through immunotherapy. It went public in January 2018 has a market cap of $1.1 billion. GV invested in its Series C as well as its Series C-1 in 2016 and 2017 respectively, and its stake is currently worth $45.14 million.
Denali Therapeutics creates therapies for neurodegenerative diseases like Alzheimer's and Parkinson's and went public in December 2017 and currently has a market cap of $1.86 billion.
There's a good chance 2018 will bring more excitement: Nasdaq's head of healthcare listings recently predicted that biotech M&A will be hot this year and that we could see 30+ total biotech IPOs.
GV portfolio company 23andMe is expected to file before the end of the year.